The potential of Heat Shock Proteins (HSPs) has sparked considerable research and industry interest. Results from early phase studies are encouraging — are they the next big thing in cancer therapy?
Heat shock proteins have emerged as a promising target for cancer therapy and Espicom has identified a number of projects currently under clinical investigation that span both Phase I and II clinical trials. The majority of agents progressing through development are HSP90 inhibitors, with one HSP-based anticancer vaccine.
As a chaperone protein, HSP90 plays an important role in regulating the function and activity of numerous clients, or signalling, proteins that have been shown to be critical to cancer cell growth, proliferation and survival. The inhibition of HSP90 leads to degradation of these client proteins and the subsequent death of cancer cells dependent on their activity.
While early drugs in this class were dogged by drug-related toxicities, we estimate that the first improved HSP inhibitors will begin to enter the market in 2014/2015, offering further treatment options for patients with advanced disease, an area of high unmet clinical need.
If you would like to read more on the Heat Shock Proteins Guide, to see what is included in the report, or to invest immediately, please click on our link below:
Heat Shock Proteins
Please feel free to leave a comment and i'll get back to you as soon as possible, regards, Paul.
Posts
No comments:
Post a Comment